JIP
UBX

Jaffetilchin Investment Partners’s Unity Biotechnology UBX Stock Holding History

Jaffetilchin Investment Partners’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50
Closed -$74 – 1245
2024
Q3 		$74 Buy
+50
New +$73 ﹤0.01% 1334

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return

Jaffetilchin Investment Partners's UBX Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of Unity Biotechnology (UBX) in Q4 2024, closing a stake of 50 shares — an estimated $74 sold.

Jaffetilchin Investment Partners first reported a position in UBX in Q3 2024 and held it in 1 quarter. The position peaked at $74 in Q3 2024. 37 funds tracked by Wall St. Rank hold UBX as of Q4 2024.

  • Jaffetilchin Investment Partners reported no remaining Unity Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 50 Unity Biotechnology shares in Q4 2024, an estimated $74.
  • Jaffetilchin Investment Partners first reported a position in Unity Biotechnology in Q3 2024 and held it in 1 quarter.
  • Jaffetilchin Investment Partners's Unity Biotechnology position peaked at $74 in Q3 2024.
  • 37 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.